Imagen’s methodology produces phenotypic clinical drug response data, leveraging automated fluorescence microscopy (high content analysis). We use a proprietary cell medium to enhance cell growth and select for specific neoplastic (cancerous) cell proliferation, thereby creating a low-passage, clinically-relevant patient-derived cancer (PDC) model. These PDC models have been shown to recapitulate various biological characteristics of the parent tumour.
Imagen develop both 2D and sophisticated 3D PDC models, for more complex requirements.
We’re working hard to improve outcomes for cancer patients by accelerating drug discovery and the development of new cancer therapies. Our vision is to create the world’s leading biobank of clinically relevant patient-derived cancer (PDC) models whilst building one of the most comprehensive and diverse big data sets available in cancer research.
